Navamedic ASA Enhances Distribution Agreement for Imdur®
Navamedic ASA has entered into a renewed distribution agreement with TopRidge Pharma Limited for the widely-used medication Imdur®. This agreement is set to last until 2032 and includes potential expansions for additional products in the future.
Chief Executive Officer Kathrine Gamborg Andreassen expressed excitement over this partnership renewal. "It is a pleasure to announce that we have agreed with our great partner TopRidge Pharma to extend our distribution agreement for Imdur until 2032. Despite the competition, Imdur remains a crucial product for us and is well-received in various markets including the Nordics and regions beyond. Patients value this treatment and often rely on it for extended periods," she stated.
Imdur® is a prescription medication that operates as an effective treatment for preventing angina pectoris, a type of chest pain associated with heart disease. Since its introduction in Europe in 1985, it has established itself as a reliable choice amongst patients who require long-term care.
With the renewal of this agreement, Navamedic is optimistic about enhancing collaboration with TopRidge Pharma. The steadfast support from TopRidge in securing Marketing Authorisations and ensuring consistent product availability has been instrumental in maintaining the product's success.
The effective date for this renewed agreement will be January 1, 2025. Although signed on April 29, 2025, the revised terms will come into effect earlier, ensuring a seamless transition and continued supply for patients.
About Navamedic ASA
Navamedic ASA is a prestigious Nordic pharmaceutical company dedicated to improving the quality of life for individuals. By being a trusted supplier of high-quality prescription medications, consumer health treatments, and hospital products, Navamedic serves both hospitals and pharmacies effectively.
Commitment to Health and Wellness
Navamedic’s ever-expanding product portfolio tackles critical public health issues, focusing on areas like obesity, Parkinson's disease, and antibiotic therapies. This careful selection reflects the company's mission to empower individuals to lead healthier, more fulfilling lives.
Understanding Market Needs
What distinguishes Navamedic is its strong commitment to grasping the needs and preferences of the markets it operates in. Their local insight enables them to better cater to the unique health requirements of each country, positioning the company as a preferred partner for those seeking to expand across the Nordics and Benelux regions.
Financial Transparency
Founded in 2006, Navamedic is listed on the Oslo Stock Exchange under the ticker symbol NAVA. The company maintains its headquarters in Oslo, Norway, committing to transparency and accountability in its offerings.
Innovations and Future Directions
Looking forward, Navamedic is eager to explore new therapeutic collaborations and innovations that will enhance its product offerings, ensuring that it remains at the forefront of the pharmaceutical industry.
Frequently Asked Questions
What is the significance of the renewed agreement for Imdur®?
The renewed agreement ensures a stable supply and continued market presence of Imdur®, benefiting patients who rely on this medication.
How long will the distribution agreement last?
The distribution agreement is set to last until 2032, with options for including new products in the future.
Who is the partner company in this agreement?
TopRidge Pharma Limited is the partner company in the renewed distribution agreement for Imdur®.
What does Navamedic ASA specialize in?
Navamedic ASA specializes in providing high-quality prescription medicines, consumer health products, and hospital supplies.
Where is Navamedic ASA headquartered?
Navamedic ASA is headquartered in Oslo, Norway, where it has been actively participating in the pharmaceutical market since 2006.
